Physician profile
Selwyn E Levine
NPI 1184692105
$4,955.63
in general payments reported to CMS, 2019-2025
38 companies · $1,313 in 2025
The $1,313 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $714 · 2020: $204 · 2021: $335 · 2022: $530 · 2023: $1,167 · 2024: $693 · 2025: $1,313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,863 · Education: $309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,863.42 |
| Education | $308.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,098.40 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $785.38 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Philips North America LLC | $373.71 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Boehringer Ingelheim Pharmaceuticals, INC. | $328.39 | 2019-2025 | Ofev, Jascayd |
| Verona Pharma, INC. | $323.11 | 2025 | Ohtuvayre |
| Sanofi-Aventis U.S. LLC | $274.93 | 2023-2025 | |
| Mylan Specialty L.P. | $223.52 | 2020-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $182.82 | 2019-2025 | Dupixent |
| Insmed, INC. | $154.83 | 2022-2025 | Brinsupri, Arikayce |
| Genzyme Corporation | $145.92 | 2019-2025 | |
| Genentech USA, INC. | $110.08 | 2019-2020 | |
| Electromed, INC. | $106.06 | 2023-2024 | Smartvest |
| United Therapeutics Corporation | $99.37 | 2023-2025 | Tyvaso, Tyvaso |
| Grifols USA, LLC | $87.96 | 2020-2024 | Prolastin-C Liquid, Xembify |
| Viatris Specialty LLC | $74.87 | 2025 | Yupelri |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $69.98 | 2022-2024 | Verquvo, Belsomra, Steglatro |
| Avadel Cns Pharmaceuticals, LLC | $53.02 | 2025 | Lumryz |
| Teva Pharmaceuticals USA, INC. | $48.97 | 2019-2022 | |
| Vifor Pharma, INC. | $46.38 | 2024-2025 | Zemaira |
| Pfizer INC. | $45.50 | 2022-2025 | |
| Harmony Biosciences LLC | $43.27 | 2021-2023 | Wakix |
| Amgen INC. | $34.00 | 2025 | |
| Baxter Healthcare | $28.71 | 2023 | Hillrom - Life 2000 Ventilation System |
| Sunovion Pharmaceuticals INC. | $17.81 | 2019 | |
| Idorsia Pharmaceuticals US INC | $16.81 | 2023 | Quviviq |
| Actelion Pharmaceuticals US, INC. | $16.42 | 2023 | Opsumit |
| Alexion Pharmaceuticals, INC. | $15.68 | 2023 | Ultomiris |
| Csl Behring | $15.60 | 2020 | |
| Inogen, INC. | $14.89 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Covis Pharma Gmbh | $14.84 | 2023 | |
| Advanced Respiratory, INC | $14.82 | 2021 | |
| Abbvie INC. | $14.01 | 2024 | |
| Jazz Pharmaceuticals INC. | $13.89 | 2022 | |
| Azurity Pharmaceuticals, INC. | $13.39 | 2024 | Horizant |
| Angiodynamics, INC. | $13.26 | 2021 | |
| Circassia INC. | $12.35 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.44 | 2019 | |
| Nabriva Therapeutics, Plc | $11.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Selwyn Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.